Cabezón, M. Malinverni, R. Bargay, J. Xicoy, B. Marcé, S. Garrido, A. Tormo, M. Arenillas, L. Coll, R. Borras, J.
...
Published in
Clinical Epigenetics
BackgroundEpigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates to HMA are low and there is an unmet n...
Sandhu, Karamjeet S Dadwal, Sanjeet Yang, Dongyun Mei, Matthew Palmer, Joycelynne Salhotra, Amandeep Al Malki, Monzr Aribi, Ahmed Ali, Haris Khaled, Samer
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
The combination of hypomethylating agents with the selective Bcl-2 inhibitor venetoclax (HMA-VEN) has emerged as a highly active regimen in patients with acute myelogenous leukemia (AML) in both the upfront and relapsed/refractory (r/r) settings. We report our early experience with a cohort of patients who were able to proceed to allogeneic hematop...
Pepe, Sara Scalzulli, Emilia Colafigli, Gioia Di Prima, Alessio Diverio, Daniela Mancini, Marco Latagliata, Roberto Martelli, Maurizio Foà, Robin Breccia, Massimo
...
Published in
Annals of hematology
Predictive factors of response to hypomethylating agents (HMA) in elderly acute myeloid leukemia (AML) patients remain unclear in the real-life setting and no direct comparison between azacitidine (AZA) and decitabine (DEC) has been carried out. We retrospectively evaluated 110 AML patients treated with HMA (78 AZA, 32 DEC) as first-line therapy ou...
Cogan, Jacob C. Liu, Yuxuan Amengual, Jennifer E.
Published in
Current Treatment Options in Oncology
Epigenetic mutations are frequent and pathogenic in select subtypes of lymphoma, and agents modulating DNA and histone methylation—such as inhibitors of DNMT and EZH2, respectively—have demonstrated promise in treating these diseases. In particular, lymphomas derived from the germinal center—GC-DLBCL, FL, and AITL—are all characterized by epigeneti...
Talati, Chetasi Goldberg, Aaron D Przespolewski, Amanda Chan, Onyee Ali, Najla Al Kim, Jongphil Famulare, Chris Sallman, David Padron, Eric Kuykendall, Andrew
...
Published in
Leukemia research
Outcomes in patients with secondary acute myeloid leukemia (sAML) (including therapy related myeloid neoplasms and AML with myelodysplasia related changes (MRC)) are poor. Patients treated with hypomethylating agents (HMAs) for antecedent hematological malignancy (AHM) have suboptimal responses to induction chemotherapy upon transformation to AML. ...
Mulvey, Erin Ruan, Jia
Published in
Journal of Hematology & Oncology
Peripheral T cell lymphomas are heterogeneous diseases which remain treatment challenges. Recent advances in molecular and genomic profiling have provided unprecedented insight into disease pathogenesis driven by distinct cells of origins and molecular pathways. The discovery and clinical application of molecular biomarkers in PTCL subtypes has the...
Griffiths, Elizabeth A Carraway, Hetty E Chandhok, Namrata S Prebet, Thomas
Published in
Leukemia research
Acute myeloid leukemia (AML) is primarily a disease of older adults. Many older patients with AML are not candidates for intensive chemotherapy regimens aimed at inducing remission before transplantation. The prognosis for this patient population remains poor, with 5-year overall survival (OS) rates of less than 10 %. At present, there is no standa...
Hospital, Marie Anne Vey, Norbert
Published in
Current Oncology Reports
Purpose of ReviewTo understand how myelodysplastic syndromes (MDS) transform to AML and to describe how transformation can be predicted and prevented.Recent FindingsRecent genomic analyses have shown that MDS progression to AML is associated with clonal expansion and clonal evolution. Mutation profiles of MDS change during progression and new mutat...
Bewersdorf, Jan Philipp Giri, Smith Wang, Rong Williams, Robert T Tallman, Martin S Zeidan, Amer M Stahl, Maximilian
Published in
Haematologica
Appelbaum, Frederick R
Published in
Best practice & research. Clinical haematology
With improvements in the safety of allogeneic hematopoietic cell transplantation, disease recurrence following the procedure is now the most frequent reason for treatment failure. Administration of maintenance therapy after transplantation is one way to try and prevent recurrence. This paper provides a brief review of the topic. Copyright © 2019. P...
